Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the safety and tolerability of switching from donepezil
to an initial dose of 5cm^2 rivastigmine patch formulation in patients with probable
Alzheimer's Disease (MMSE 10-24). The study included a 5-week, open-label, randomized period
followed by a 20-week open-label extension period. Patients were randomized to either an
immediate switch from donepezil to rivastigmine patch formulation or to a switch to
rivastigmine patch formulation following a 7-day withdrawal period.